A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors

Oncoimmunology
Riccardo TurriniAntonio Rosato

Abstract

The use of monoclonal antibodies (mAb) for the diagnosis and treatment of malignancies is acquiring an increasing clinical importance, thanks to their specificity, efficacy and relative easiness of use. However, in the context of Epstein-Barr virus (EBV)-related malignancies, only cancers of B-cell origin can benefit from therapeutic mAb targeting specific B-cell lineage antigens. To overcome this limitation, we generated a new mAb specific for BARF1, an EBV-encoded protein with transforming and immune-modulating properties. BARF1 is expressed as a latent protein in nasopharyngeal (NPC) and gastric carcinoma (GC), and also in neoplastic B cells mainly upon lytic cycle induction, thus representing a potential target for all EBV-related malignancies. Considering that BARF1 is largely but not exclusively secreted, the BARF1 mAb was selected on the basis of its ability to bind a domain of the protein retained at the cell surface of tumor cells. In vitro, the newly generated mAb recognized the target molecule in its native conformation, and was highly effective in mediating both ADCC and CDC against BARF1-positive tumor cells. In vivo, biodistribution analysis in mice engrafted with BARF1-positive and -negative tumor cells confirmed...Continue Reading

References

Apr 15, 1990·International Journal of Cancer. Journal International Du Cancer·L KarranB E Griffin
Jun 1, 1988·Virology·G HatfullP J Farrell
Apr 6, 2004·Oncogene·Alhousseynou SallTadamasa Ooka
Oct 29, 2004·Nature Reviews. Cancer·Lawrence S Young, Alan B Rickinson
Sep 6, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Karim HoualiTadamasa Ooka
Jun 6, 2008·Virology Journal·Sylvie Fiorini, Tadamasa Ooka
Jun 12, 2008·International Journal of Cancer. Journal International Du Cancer·Debora MartorelliRiccardo Dolcetti
Jun 19, 2009·International Journal of Cancer. Journal International Du Cancer·Elisa PasiniRiccardo Dolcetti
Aug 21, 2012·Nature Structural & Molecular Biology·Jonathan ElegheertSavvas N Savvides
Feb 26, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B FrigerioM Figini
Sep 3, 2013·Reviews in Medical Virology·Eveline K HoebeJaap M Middeldorp
Sep 1, 2015·Critical Reviews in Oncology/hematology·Esmeralda Chi-Yuan TeoColin Phipps
Mar 25, 2016·Cancer Immunology Research·Damiana Antonia FaèRiccardo Dolcetti

❮ Previous
Next ❯

Citations

Apr 7, 2020·Expert Opinion on Therapeutic Targets·Valentin BalochePierre Busson
Jan 19, 2018·Reviews in Medical Virology·Habibollah Mirzaei, Ebrahim Faghihloo
Jul 28, 2020·Cancers·Angela Kwok-Fung LoLawrence S Young
Apr 10, 2018·Cancer Treatment Reviews·Madiha NaseemHeinz-Josef Lenz

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
enzyme-linked immunosorbent assay
fluorescence imaging
flow cytometry
dot Blot
enzyme-linked

Software Mentioned

MedCalc
QuantityOne
LivingImage
BLAST

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.